From Gsk a monoclonal for four eosinophilic pathologies

Mepolizumab, a monoclonal antibody resulting from GSK research, is the only one to be reimbursed in Italy for four three pathologies in addition to severe asthma: chronic rhinosinusitis with nasal polyposis, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. This was discussed at the event ‘Precision therapy for eosinophilic diseases is done in four with mepolizumab’ organized by GSK in Milan.